Results 181 to 190 of about 108,435 (311)

Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review [PDF]

Jozélio Freire de Carvalho, Thelma Larocca Skare   +1 more
openalex   +1 more source

Intravenous Immunoglobulin Controls Th17 Cell-Mediated Osteoclastogenesis [PDF]

, 2019
Kyoung‐Woon Kim, Hae‐Rim Kim, Bo‐Mi Kim, Ji‐Yeon Won, Kyung‐Ann Lee, Sang‐Heon Lee   +5 more
openalex   +1 more source

Risk factors for relapse in ANCA‐associated vasculitis among patients with relapse after induction of remission with rituximab

Arthritis &Rheumatology, Accepted Article.
Objective To determine risk factors for relapse of ANCA‐associated vasculitis (AAV) after re‐induction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post‐hoc analysis of the RITAZAREM clinical trial. Patients 15 years or older with AAV and a positive test for anti‐proteinase‐3 (PR3‐) or anti‐myeloperoxidase ...
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators   +10 more
wiley   +1 more source

Combination Treatment of Persistent SARS-CoV-2 Infection with Dual Antiviral Therapy and Intravenous Immunoglobulin: A Novel Approach. [PDF]

J Clin Med
Blizou M, Lampadakis S, Karofylakis E, Blizou A, Thomas K, Prountzos S, Papavasileiou V, Raptakis T, Manali ED, Papiris SA, Loukides S, Antonogiannaki EM.   +11 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

Arthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, The TULIP‐SC investigators   +12 more
wiley   +1 more source

Efficacy of Low-Dose Intravenous Immunoglobulin Combined With Immunosuppression Modification in the Treatment of BK Polyomavirus Nephropathy: A Case Series. [PDF]

Cureus
Eswarappa M, George J, Kc G, R R, M S G, Prabhu PP, Reddy H, Yousuff M, Veluru R.   +8 more
europepmc   +1 more source

Breaking the cycle: A comparison between intravenous immunoglobulins and high dosage prednisone in the treatment of medically intractable epilepsy in children [PDF]

, 2017
Richard Tang‐Wai, Janette Mailo, Bernard Rosenblatt   +2 more
openalex   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Efficacy Analysis of a 12-Cytokine Panel for the Diagnosis of Kawasaki Disease and Prediction of Intravenous Immunoglobulin Resistance. [PDF]

J Inflamm Res
Kong W, Gao L, Hu J, Xu Z, Zhang Q, Wang Y, Fu S, Xie C, Gong F.   +8 more
europepmc   +1 more source

Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Children with primary immunodeficiency (PID) and secondary antibody deficiency (SAD) often require immunoglobulin replacement therapy due to low plasma immunoglobulin G (IgG) levels and recurrent infections. Existing pharmacokinetic models for immunoglobulin in PID patients predominantly focus on adults, with limited attention to ...
Iek Leng Cheng, Zhong Hui Huang, Austen Worth, Claire Booth, Joseph F. Standing   +4 more
wiley   +1 more source